5-(Morpholin-4-yl)pyrazine-2-carboxylic acid → HCID 178523659, Verbindung
Reaktionsgleichung
Cl.Cl.[O:3]1[C:8]2=[CH:9][CH:10]=[CH:11][C:7]2=[CH:6][C:5]([CH:12]2[CH2:17][CH2:16][CH2:15][CH2:14][N:13]2[CH2:18][CH2:19][C@H:20]2[CH2:25][CH2:24][C@H:23]([NH2:26])[CH2:22][CH2:21]2)=[CH:4]1.[N:27]1([C:33]2[N:34]=[CH:35][C:36]([C:39](O)=[O:40])=[N:37][CH:38]=2)[CH2:32][CH2:31][O:30][CH2:29][CH2:28]1>>[O:3]1[C:8]2=[CH:9][CH:10]=[CH:11][C:7]2=[CH:6][C:5]([CH:12]2[CH2:17][CH2:16][CH2:15][CH2:14][N:13]2[CH2:18][CH2:19][C@H:20]2[CH2:21][CH2:22][C@H:23]([NH:26][C:39]([C:36]3[CH:35]=[N:34][C:33]([N:27]4[CH2:32][CH2:31][O:30][CH2:29][CH2:28]4)=[CH:38][N:37]=3)=[O:40])[CH2:24][CH2:25]2)=[CH:4]1Komponenten
3
Versuchsvorschrift
The title compound, off-white solid (95 mg, 73%), MS (ISP) m/z=518.4 [(M+H)+], mp 202° C., was prepared in accordance with the general method of example 1 from trans-4-[2-(4-benzofuran-3-yl-piperidin-1-yl)-ethyl]-cyclohexylamine dihydrochloride (intermediate A) (100 mg, 0.25 mmol) and 5-morpholin-4-yl-pyrazine-2-carboxylic acid.
Quellen und Nachweise
- ORD-Eintrag
- ord-6a6e0d63608043c8816bed774f94a710
- Quelldatensatz
- uspto-grants-2014_12